Latest Feature

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Podcast: Haemonetics CEO Brian Concannon at MassDevice.com's DeviceTalks

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Calhoun Vision aims to disrupt ophthalmology with its light-adjustable lens

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

September 2, 2014 by Brad Perriello

Bluegrass Vascular Technologies taps former ArthroCare R&D chief Gabriele Niederauer to be its new president & CEO.

Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves

Bluegrass Vascular Technologies said it named Gabriele Niederauer its new president & CEO, hard on the heels of a Series A funding round that brought in $4.5 million for its Surfacer central venous catheter.

MassDevice.com +3 | The top 3 medtech stories for September 2, 2014

September 2, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Invacare unloads rehab devices for $23M

September 2, 2014 by Arezu Sarvestani

Invacare sells its Altimate Medical subsidiary, maker of standing-assistance devices, to Rockwood Equity Partners for about $23 million in cash.

Invacare unloads rehab devices for $23M

Invacare (NYSE:IVC) is hoping to narrow its focus and reduce its debt after divesting its Altimate Medical subsidiary for $23 million in cash.

Breast cancer: GE Healthcare wins pivotal FDA approval for 3D breast imaging

September 2, 2014 by Arezu Sarvestani

GE Healthcare wins FDA approval for its SenoClaire 3D breast tomosynthesis system, a device that could displace digital mammography as the major technology for breast cancer screening.

GE Healthcare wins pivotal FDA approval for 3D breast tomosynthesis

Imaging giant GE Healthcare (NYSE:GE) won FDA approval for its 3D breast tomosynthesis imaging system, MassDevice.com has learned.

Study: St. Jude's FFR helps boost stenting over drug therapy alone

September 2, 2014 by Arezu Sarvestani

Researchers report that St. Jude Medical's fractional flow reserve technology helps slash adverse events, especially urgent revascularizations, compared with medical therapy alone.

Study: St. Jude's FFR tech helps cut adverse events in half

Mixed results for nerve stim in heart failure for Boston Scientific, Cyberonics

September 2, 2014 by Brad Perriello

Vagus nerve stimulation for heart failure flunks a Boston Scientific clinical trial but passes a Cyberonics study, but the question is clouded by the more rigorous, sham-arm structure of the Boston Scientific trial.

Mixed results for nerve stim in heart failure for Boston Scientific, Cyberonics

Secant Medical escapes pelvic mesh cases

September 2, 2014 by Brad Perriello

Secant Medical is dismissed from hundreds of personal injury lawsuits brought over pelvic mesh it made for Boston Scientific and Johnson & Johnson.

Secant Medical escapes pelvic mesh cases

Boston Scientific closes $415 Bayer interventions buy

September 2, 2014 by Brad Perriello

Boston Scientific says it's closed the $415 million acquisition of Bayer AG's interventions unit, nearly doubling the size of its peripherals business.

Boston Scientific closes $415 Bayer interventions buy

Boston Scientific (NYSE:BSX) said today that it closed on the $415 million cash buyout of Bayer AG's interventional unit it announced last May.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp